Oncology Brands Face Uniquely Complex Market Access Challenges: A Specialized Approach for Commercial Success ...

Ted Sweetser discusses how more accurate datasets are solving problems related to getting communities access to better healthcare.

Oncology Brands Face Uniquely Complex Market Access Challenges: A Specialized Approach for Commercial Success ...

Dupixent is the first new targeted therapy to receive FDA-approval for chronic spontaneous urticaria in adults and ...

Regulatory action was based on data from the Phase III QUASAR trial, which demonstrated that Eylea HD dosed every eight weeks ...

Sonam Dubey, a partner at Beghou Consulting, discusses the potential impact of a possible ban on direct-to-consumer ...

Milan Kalawadia, CEO, North America, at Dr. Reddy’s Laboratories, goes inside the company’s new growth initiatives—and ...

Hanadie Yousef, PhD, co-founder and CEO of Juvena Therapeutics, explores the potential synergy between myopathies and obesity ...

The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to expand access to ...

Ted Sweetser discusses how the technology is providing greater insight into how marketing materials are being viewed.

Oncology Brands Face Uniquely Complex Market Access Challenges: A Specialized Approach for Commercial Success ...